ALPS12 + obinutuzumab

ALPS12 + obinutuzumab is a **combination drug** consisting of ALPS12 (which, based on available data, is a code name likely referring to a novel agent, possibly under clinical development) and **obinutuzumab**, a humanized type II glycoengineered monoclonal antibody targeting CD20 on B lymphocytes. Obinutuzumab mediates B-cell destruction by multiple mechanisms including antibody-dependent cellular cytotoxicity, antibody-dependent cellular phagocytosis, direct induction of cell death, and complement activation. It is primarily developed and manufactured by Roche/Genentech and approved for treatment of chronic lymphocytic leukemia and follicular lymphoma when used in combination with agents such as chlorambucil or bendamustine[1][2][3][4]. As of the current knowledge cut-off, specific publicly available information on ALPS12 in combination with obinutuzumab is limited; the combination implies investigational use in B-cell hematologic malignancies.

Brand names

Gazyva

Other names

ALPS12ALPS-12ALPS 12obinutuzumabGazyva